Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group.
ALPL
Alkaline phosphatase
HPP diagnosis in children
hypophosphatasia
osteomalacia
rickets
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
30
12
2022
accepted:
23
06
2023
medline:
20
11
2023
pubmed:
20
11
2023
entrez:
20
11
2023
Statut:
aheadofprint
Résumé
Hypophosphatasia (HPP) is a rare inborn error of metabolism that presents variably in both age of onset and severity. HPP is caused by pathogenic variants in the ALPL gene, resulting in low activity of tissue nonspecific alkaline phosphatase (TNSALP). Patients with HPP tend have a similar pattern of elevation of natural substrates that can be used to aid in diagnosis. No formal diagnostic guidelines currently exist for the diagnosis of this condition in children, adolescents, or adults. The International HPP Working Group is a comprised of a multidisciplinary team of experts from Europe and North America who have expertise in the diagnosis and management of patients with HPP. This group reviewed 93 papers through a Medline, Medline In-Process, and Embase search for the terms "HPP" and "hypophosphatasia" between 2005 and 2020 and that explicitly address either the diagnosis of HPP in children, clinical manifestations of HPP in children, or both. Two reviewers independently evaluated each full-text publication for eligibility and studies were included if they were narrative reviews or case series/reports that concerned diagnosis of pediatric HPP or included clinical aspects of patients diagnosed with HPP. This review focused on 15 initial clinical manifestations that were selected by a group of clinical experts.The highest agreement in included literature was for pathogenic or likely pathogenic ALPL variant, elevation of natural substrates, and early loss of primary teeth. The highest prevalence was similar, including these same three parameters and including decreased bone mineral density. Additional parameters had less agreement and were less prevalent. These were organized into three major and six minor criteria, with diagnosis of HPP being made when two major or one major and two minor criteria are present.
Identifiants
pubmed: 37982855
doi: 10.1007/s00198-023-06843-2
pii: 10.1007/s00198-023-06843-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Mornet E (2017) Genetics of hypophosphatasia. Arch Pediat 24(5S2):5S51–5S56. https://doi.org/10.1016/S0929-693X(18)30014-9
Khan AA, Josse R, Kannu P et al (2019) Hypophosphatasia: Canadian update on diagnosis and management. Osteoporos Int 30(9):1713–1722
doi: 10.1007/s00198-019-04921-y
pubmed: 30915507
Hofmann C, Girschick HJ, Mentrup B et al (2013) Clinical aspects of hypophosphatasia: an update. Clin Rev Bone Min Metabol 11(2):60–70
doi: 10.1007/s12018-013-9139-0
Rockman-Greenberg C (2013) Hypophosphatasia. Pediatr Endocrinol Rev 10(Suppl 2):380–388
pubmed: 23858621
Whyte MP (2016) Hypophosphatasia-aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12(4):233–246
doi: 10.1038/nrendo.2016.14
pubmed: 26893260
Whyte MP, Zhang F, Wenkert D et al (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone 75:229–239
doi: 10.1016/j.bone.2015.02.022
pubmed: 25731960
Offiah AC, Vockley J, Munns CF, Murotsuki J (2019) Differential diagnosis of perinatal hypophosphatasia: radiologic perspectives. Pediatr Radiol 49(1):3–22. https://doi.org/10.1007/s00247-018-4239-0
doi: 10.1007/s00247-018-4239-0
pubmed: 30284005
Colazo JM, Hu JR, Dahir KM, Simmons JH (2019) Neurological symptoms in hypophosphatasia. Osteoporos Int 30(2):469–480. https://doi.org/10.1007/s00198-018-4691-6
doi: 10.1007/s00198-018-4691-6
pubmed: 30215116
Whyte MP, Leung E, Wilcox WR, Liese J, Argente J, Martos-Moreno GÁ, Reeves A, Fujita KP, Moseley S, Hofmann C (2019) Study 011-10 investigators. Natural history of perinatal and infantile hypophosphatasia: a retrospective study. J Pediatr 209:116–124.e4
doi: 10.1016/j.jpeds.2019.01.049
pubmed: 30979546
Bangura A, Wright L, Shuler T (2020) Hypophosphatasia: current literature for pathophysiology, clinical manifestations, diagnosis, and treatment. Cureus 12(6):e8594
pubmed: 32676235
pmcid: 7362651
Fenn JS, Lorde N, Ward JM, Borovickova I (2021) Hypophosphatasia. J. Clin. Pathol. 74(10):635–640. https://doi.org/10.1136/jclinpath-2021-207426
doi: 10.1136/jclinpath-2021-207426
pubmed: 33931563
Pierpont EI, Simmons JH, Spurlock KJ, Shanley R, Sarafoglou KM (2021) Impact of pediatric hypophosphatasia on behavioral health and quality of life. Orphanet J Rare Dis 16(1):80
doi: 10.1186/s13023-021-01722-7
pubmed: 33579333
pmcid: 7881480
Del Angel G, Reynders J, Negron C, Steinbrecher T, Mornet E (2020) Large-scale in vitro functional testing and novel variant scoring via protein modeling provide insights into alkaline phosphatase activity in hypophosphatasia. Hum Mutat 41(7):1250–1262. https://doi.org/10.1002/humu.24010
doi: 10.1002/humu.24010
pubmed: 32160374
pmcid: 7317754
Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, Coburn SP, Wagy S, Griffin DM, Ericson KL, Mumm S (2015) Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone 75:229–239
doi: 10.1016/j.bone.2015.02.022
pubmed: 25731960
Tenorio J, Álvarez I, Riancho-Zarrabeitia L, Martos-Moreno GÁ, Mandrile G, de la Flor CM, Sukchev M, Sherif M, Kramer I, Darnaude-Ortiz MT, Arias P, Gordo G, Dapía I, Martinez-Villanueva J, Gómez R, Iturzaeta JM, Otaify G, García-Unzueta M, Rubinacci A et al (2017) Molecular and clinical analysis of ALPL in a cohort of patients with suspicion of Hypophosphatasia. Am J Med Genet A 173(3):601–610
doi: 10.1002/ajmg.a.37991
pubmed: 28127875
Whyte MP, Zhang F, Wenkert D, Mack KE, Bijanki VN, Ericson KL, Coburn SP (2021) Hypophosphatasia: Vitamin B6 status of affected children and adults. Bone 20(154):116204. https://doi.org/10.1016/j.bone.2021.116204
doi: 10.1016/j.bone.2021.116204
Whyte MP, Coburn SP, Ryan LM, Ericson KL, Zhang F (2018) Hypophosphatasia: biochemical hallmarks validate the expanded pediatric clinical nosology. Bone 110:96–106. https://doi.org/10.1016/j.bone.2018.01.022
doi: 10.1016/j.bone.2018.01.022
pubmed: 29360619
Villa-Suárez JM, García-Fontana C, Andújar-Vera F, González-Salvatierra S, de Haro-Muñoz T, Contreras-Bolívar V, García-Fontana B, Muñoz-Torres M (2021) Hypophosphatasia: a unique disorder of bone mineralization. Int J Mol Sci 22(9):4303
doi: 10.3390/ijms22094303
pubmed: 33919113
pmcid: 8122659
Whyte MP, Madson KL, Phillips D, Reeves AL, McAlister WH, Yakimoski A, Mack KE, Hamilton K, Kagan K, Fujita KP, Thompson DD, Moseley S, Odrljin T, Rockman-Greenberg C (2016) Asfotase alfa therapy for children with hypophosphatasia. JCI Insight 1(9):e85971. https://doi.org/10.1172/jci.insight.85971
doi: 10.1172/jci.insight.85971
pubmed: 27699270
pmcid: 5033855
Bishop N, Munns CF, Ozono K (2016) Transformative therapy in hypophosphatasia. Arch. Dis. Child. 101(6):514–515. https://doi.org/10.1136/archdischild-2015-309579
doi: 10.1136/archdischild-2015-309579
pubmed: 26992417
Karbasy K, Lin DC, Stoianov A, Chan MK, Bevilacqua V, Chen Y, Adeli K (2016) Pediatric reference value distributions and covariate-stratified reference intervals for 29 endocrine and special chemistry biomarkers on the Beckman Coulter Immunoassay Systems: a CALIPER study of healthy community children. Clin Chem Lab Med 54(4):643–657. https://doi.org/10.1515/cclm-2015-0558
doi: 10.1515/cclm-2015-0558
pubmed: 26457782
Placeholder for diagnosis/methods paper
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7):e1000097
doi: 10.1371/journal.pmed.1000097
pubmed: 19621072
pmcid: 2707599
Simmons JH, Rush ET, Petryk A, Zhou S, Martos-Moreno GÁ (2020) Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: a pooled post hoc analysis of asfotase alfa clinical trial data. Bone. 137:115413. https://doi.org/10.1016/j.bone.2020.115413
doi: 10.1016/j.bone.2020.115413
pubmed: 32417537
Mornet E, Taillandier A, Domingues C, Dufour A, Benaloun E, Lavaud N, Wallon F, Rousseau N, Charle C, Guberto M, Muti C, Simon-Bouy B (2021) Hypophosphatasia: a genetic-based nosology and new insights in genotype-phenotype correlation. Eur J Hum Genet 29(2):289–299. https://doi.org/10.1038/s41431-020-00732-6
doi: 10.1038/s41431-020-00732-6
pubmed: 32973344
Szabo SM, Tomazos IC, Petryk A et al (2019) Frequency and age at occurrence of clinical manifestations of disease in patients with hypophosphatasia: a systematic literature review. Orphanet J Rare Dis 14(1):85
doi: 10.1186/s13023-019-1062-0
pubmed: 31023354
pmcid: 6485115
Wenkert D, McAlister WH, Coburn SP, Zerega JA, Ryan LM, Ericson KL, Hersh JH, Mumm S, Whyte MP (2011) Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res 26:2389–2398. https://doi.org/10.1002/jbmr.454
doi: 10.1002/jbmr.454
pubmed: 21713987
Bangura A, Wright L, Shuler T (2020) Hypophosphatasia: current literature for pathophysiology, clinical manifestations, diagnosis, and treatment. Cureus 12(6):e8594. https://doi.org/10.7759/cureus.8594
doi: 10.7759/cureus.8594
pubmed: 32676235
pmcid: 7362651
Genest F, Claußen L, Rak D, Seefried L (2021) Bone mineral density and fracture risk in adult patients with hypophosphatasia. Osteoporos Int 32(2):377–385. https://doi.org/10.1007/s00198-020-05612-9
doi: 10.1007/s00198-020-05612-9
pubmed: 32879991